12 research outputs found
Recommended from our members
OER: opening doors and breaching boundaries
The white paper on higher education (BIS, 2011) refers to the government’s social mobility strategy, Opening doors, breaking barriers (HM Government, 2011). The expressed aspirations of the OER (open educational resources) community resonate with the white paper’s three central challenges: attaining sustainability; improving the learner experience; and taking responsibility for social mobility. Lee (2008), writing of the potential of OER, recalls the actions of the eponymous Jude the Obscure, whose anger at exclusion from university led him to graffiti the closed gates of ‘Biblioll College’ (Hardy, 1895). However, while both groups agree that change is necessary, there is little common ground in mapping solutions to opening doors to HE
Recommended from our members
Reuse and Repurposing of Online Digital Learning Resources within UK Higher Education: 2003-2010
This research set out to examine developments in reuse and repurposing of online digital resources within higher education (HE) in the United Kingdom (UK) over a period (2003-2010), when the emphasis of educational resource reuse and repurposing activity shifted from reusable learning objects (RLO) to open educational resources (OER). It aims to contribute to understanding of this transition, and locates this shift within a broader picture of UK HE activity within the UK, and a wider understanding of reuse of learning resources in digital, online form.
The research presents a review and critical examination of the environment in which reuse practice occurred. It does this through macroenvironmental, mesoenvironmental and microenvironmental level reviews. The microenvionmental review is presented through research analysis of five case examples from UK HE and a sixth example from HE in Ireland. The mesoenvironmental review examines the significant changes in resource facilitation and practice during the research period. This thesis is particularly concerned with identifying and understanding how reuse of digital online learning resources was facilitated in practice, and whether reuse occurred, or occurred in the form(s) anticipated.
The thesis identifies and examines themes and factors which appeared to have influenced, or had potential to influence, reuse in each case. Cross-case comparison offers a synthesis of the research observations. Finally, a structured approach to classifying factors is suggested based on this research. This leads to generalisable recommendations of how to facilitate digital online resource reuse in the future
Recommended from our members
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.
Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, and Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020. Interventions: The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (n = 143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (n = 152), or no hydrocortisone (n = 108). Main Outcomes and Measures: The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%). Results: After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (n = 137), shock-dependent (n = 146), and no (n = 101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0 (IQR, -1 to 15), 0 (IQR, -1 to 13), and 0 (-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively. Conclusions and Relevance: Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions. Trial Registration: ClinicalTrials.gov Identifier: NCT02735707
Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19
IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19.
Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19.
DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022).
INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days.
MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes.
RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively).
CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570
Distribution of surface water partial CO2 pressure in the English Channel and in the Southern Bight of the North Sea
peer reviewedaudience: researcher, professional, studentThe concentrations of dissolved CO2 dissolved oxygen and chlorophyll have been determined in the surface seawater of the English Channel and of the Southern Bight of the North Sea in June 1992, April–May 1993 and September–October 1993. The partial pressure of CO2(PCO2) displays large spatial and temporal variations ranging from 100 ppm up to 670 ppm. The relationship between seawater pCO2 and chlorophyll distribution is discussed and compared with data recently obtained in the North Atlantic by A. J. Watson, C. Robinson, J. E. Robertson, P. J. le B. Williams and J. R. Fasham (1991)Nature, 350, 50–53. Air-sea CO2 fluxes have been calculated from wind speed and pCO2 data and, due to the combined effect of both of those parameters, the flux can be as high as about 150 mmol m−2 d−1. This implies that shelves could play an appreciable role in the global C budget. Further extended C02 level measurements should be made to improve flux estimations for the coastal zone on a global basis
Host race formation in the Acari
Host race formation generates diversity within species and may even lead to speciation. This phenomenon could be particularly prevalent in the Acari due to the often intimate interaction these species have with their hosts. In this review, we explore the process of host race formation, whether it is likely to occur in this group and what features may favour its evolution. Although few studies are currently available and tend to be biased toward two model species, results suggest that host races are indeed common in this group, and more likely to occur when hosts are long-lived. We discuss future directions for research on host-associated adaptations in this group of organisms and the potential relevance of host race formation for the biodiversity of mites and ticks
Monogenic Early-Onset Lymphoproliferation and Autoimmunity: The Natural History of STAT3 GOF Syndrome.
Background
In 2014, germline signal transducer and activator of transcription (STAT) 3 gain-of-function (GOF) mutations were first described to cause a novel multisystem disease of early-onset lymphoproliferation and autoimmunity.
Objective
This pivotal cohort study defines the scope, natural history, treatment, and overall survival of a large global cohort of patients with pathogenic STAT3 GOF variants.
Methods
We identified 191 patients from 33 countries with 72 unique mutations. Inclusion criteria included symptoms of immune dysregulation and a biochemically confirmed germline heterozygous GOF variant in STAT3.
Results
Overall survival was 88%, median age at onset of symptoms was 2.3 years, and median age at diagnosis was 12 years. Immune dysregulatory features were present in all patients: lymphoproliferation was the most common manifestation (73%); increased frequencies of double-negative (CD4−CD8−) T cells were found in 83% of patients tested. Autoimmune cytopenias were the second most common clinical manifestation (67%), followed by growth delay, enteropathy, skin disease, pulmonary disease, endocrinopathy, arthritis, autoimmune hepatitis, neurologic disease, vasculopathy, renal disease, and malignancy. Infections were reported in 72% of the cohort. A cellular and humoral immunodeficiency was observed in 37% and 51% of patients, respectively. Clinical symptoms dramatically improved in patients treated with JAK inhibitors, while a variety of other immunomodulatory treatment modalities were less efficacious. Thus far, 23 patients have undergone bone marrow transplantation, with a 62% survival rate.
Conclusion
: STAT3 GOF patients present with a wide array of immune-mediated disease including lymphoproliferation, autoimmune cytopenias, and multisystem autoimmunity. Patient care tends to be siloed, without a clear treatment strategy. Thus, early identification and prompt treatment implementation are lifesaving for STAT3 GOF syndrome.
Key word